SPDR Series Trust SPDR S&P Biotech ETF (XBI)

On Monday, we called for a trading bottom in healthcare stocks. We also saw momentum picking for two Health Science sectors: small- to mid-cap biotechs, and MedTech. Here is a closer look at these spaces.

The small-cap biotech firm called the proposal "significantly undervaluing" the company and added that it was not in the best interest of its shareholders.

The brokerage pointed to the company’s recent discontinuation of its NTLA-3001 program for alpha-1 antitrypsin deficiency-associated lung disease, reducing near-term growth prospects.

The analyst highlighted that major pharmaceutical companies are already pursuing GLP-1-based therapies for MASH, but he believes efruxifermin could complement these treatments.

The agreement, which spans up to four years, allows 17 participating countries access to Moderna’s vaccine in various formats.

Biotech stocks got little help from the JPM Conference despite some recovery to the general market.

Investors may be underestimating Trump's potential push for fiscal discipline, making long-term bonds and rate-sensitive sectors attractive bets.

Oppenheimer earlier this month listed Viking as one of five biotech companies that could be prime candidates for an "aspirational" takeover.

The company’s stock declined nearly 60% in 2024 and has lost an additional 21% in 2025, with this latest setback further dampening investor confidence.

Stocks gave back all of Monday’s gains and then some today. Monday’s panic buyers were mercilessly punished for going nuts during the spree.

Bird flu has severely impacted poultry farms and cattle herds across 16 states, marking the worst outbreak of its kind.

The healthcare sector is lagging over the past year and recent quarter with the XLV flat for 2024 and down over 4% for the recent quarter.

In a year like 2024, it is easy to forget the fact that since 1927 “Value” has outperformed “Growth” by 4.4% per year:

Biotech shares continued their slide which began in early November and got no help from small caps which also sold off through December.

It’s not a bear market for biotech yet it just feels that way because recent trends are down and healthcare stocks are not a stabilizing force.

The Federal Reserve's final meeting of the year has historically caused significant moves in 20 ETFs. A rate cut is expected, but the focus is on the Fed's forward guidance and projections.

It’s been a very difficult month for the healthcare sector not only because of disappointing company news but also disruption caused by the election and future policy issues.

Stocks managed to grind their way higher on the day, while rates and the dollar rebounded from yesterday’s declines.

Biotech stocks are poised for a recovery in a seasonally strong period through January 2025.

The biotech sector's breakout attempt post-election reversed sharply, with ETFs like IBB and XBI falling and invalidating the long-term bullish setup.

The market  was quiet today but we should still expect some gains through year -end albeit a bit choppy.

To gain an edge, this is what you need to know today.

In this video, I take a look at how the markets have turned around after the US election. I also review a new long setup in Pinnacle West Capital.

If you have been reading our posts you know that some of the big biotech winners have taken a hit after earnings : LLY, MRK and REGN. But ABBV, GILD, LLY, and VRTX remain among the top performers.

Everyone who follows the stock market knows that a huge rally occurred on Wednesday, and by Friday, new highs were set for many of the most important stocks, ETFs, and Indexes. Tuesday's rally off the lows hinted at the rally coming on Wednesday.